Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (1183)	5/20/2000 4:52:00 PM
From: SnowShredder	Respond to of 4474

Hi Scott, I understand your pts about your hypothetical speculation that RAPID is a stronger promoter than others, but that pt can be used with any promoter that qualifies. Believe me I know that RAPID is promising, as I enjoyed their presentations @ Keystone, not to mention the people that I met very personable. Putting in endogenous promoters/enhancers along with the transgene is a ways off, but would be the eventual preferred method of control if possible (although there will be conditions where it will not be possible).>imo< RAPID will probably come to fruition long before endogenous control, but may eventually lose some market to endogenous control. BWDIK? Ariad does not produce transgenes to interact with endogenous genes. Recall ARGENT/RAPID are episome-like, inducible cassettes that are activated by the dimerized transcription factors previously infected into the cell. Ariad's constructs are self contained systems with all the elements necessary (in the cellular environment) to transcribe and translate a gene. I understand that RAPID is an inducible promoter, but if one uses a spliceosome then an inducible promoter may not be necesarry in that the gene is repaired @ the RNA level, and endogenous gene regulation is used to regulate gene product expression. intronn.com Please explain the VLTS system to me. Perhaps it is better than ARGENT and RAPID. My last contact with Tet-based systems indicatedthey had significant leakiness problems. Is that still the case? Is Tet-off tight? VLTS uses a mifepristone-inducible expression...from what I can remember, which isn't much, is that it is also tight, and Invitrogen is marketing it to research labs. The Tet On system was leaky, and the Tet Off system was tight. I'm sure that they've made improvements since my last look, which wasn't recent : ) if anyone ever claims a growth factor, cytokine, prostaglandin, antioxidant, radical gas, etc. will 'cure' a neurological pathology, please, please, please ignore them. Thanks for the tip, I just know that the brain is too complex for me >gg< Best of Luck, Where'd He Go?

To: scott_jiminez who wrote (1183)	5/21/2000 5:52:00 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 4474

OT Neuro <Needless to say be very, very careful of biotechnology companies in this field> Cephalon, Neurocrine, Neurogen, NPS, Gliatech, Cortex, NTII, and of course my little cnsi--those are the ones I try to follow, and I certainly moniotor the threads and especially what Neuro- investment has to say--which of those companies have you personally steered away from?? don't tell me you are one of the Gliatech bears--I own glia, npsp, nrgn and cnsi. Harry Tracy sure seems well-informed (as he is the only neuro guru I can think of--and even he is always full of disclaimers). In your opinion is Neuroinvestment worth the price of the subscription--and you can PM me on that question (as well as everybody else with an opinion--I am not interested in starting a pissing match on which newletters to buy and which to steer away from--I also tried the sampler of Biotech navigator-- so any PMs with opinions on that one are invited too). I let my trial in Neuro lapse, but am itching to start it up again--I suspect Harry is much better informed than, say, McCamant, Michael Murphy, or for that matter Von Emster or any of the fund managers, at least when it comes to neuro. Finally, have you adjusted your target yet? Message 13118757 perhaps you meant a $2.0-3.0 dollar stock? I am less and less willing to dig my heels in on that one and admit defeat, despite a few big owners in there at 13% each, I am thinking this one is going out at a buck and a half to Bayer and I wasted my time-- plus your comment about any one thing doing anything for a neuro pathway suggests that your DD on at least one company has turned up a big goose egg. What do you think of Elan and the Alzheimer vaccines out there? Okay that is enough of the questions--I don't know why I even follow these neuros and gene therapy companies, they are exceedingly complex and I'll bet I am going to get further mixed signals now (if you do respond). In fact, speaking of gene therapy, the only one I own right now is TGEN--and that is partly because it is here in Seattle. What is your gene therapy watch lists--list of symbols? I noticed nobody has bothered to post to the Neuro thread yet--too hopelessly complicated a subject? Subject 33855